Thermalin Diabetes develops new insulin molecules, novel formulations, and devices built on 25 years of insulin research. The company leverages significant IP derived from work by Dr. Michael Weiss, chairman of biochemistry at Case Western Reserve Medical School. Its products aim to address unmet clinical needs and enable new delivery technologies. Thermalin says it plans to reach rapidly developing markets. Financially, the company has initiated a Series B and completed a first tranche of financing. Thermalin Diabetes is a Cleveland, OH-based biopharmaceutical company developing new insulin treatments for patients with diabetes. Its work is built on technology developed by Dr. Michael A. Weiss at Case Western Reserve Medical School. The company’s patent-pending compounds include rapid-, intermediate- and long-acting insulin analogs. With patents expiring on existing analogs in the next three to four years, Thermalin aims to position its compounds for commercialization. The company plans to form partnerships with large pharmaceutical companies to market innovative insulin therapies and to build a substantial new employer in Northern Ohio. It recently secured a $250,000 investment commitment from JumpStart Ventures to validate the analogs' characteristics, secure a manufacturer, and advance the investigational new drug (IND) process with the FDA.

Total raised

$6M

Funding rounds

2

Latest round

Series B

Latest activity

Jul 2014